Will 'Vant' Deal Really Fulfill Dainippon's Needs?
Executive Summary
Sumitomo Dainippon's planned $3bn deal with Roivant goes some way to fulfilling the Japanese firm's strategic needs, but investors appear cool and questions remain.
You may also be interested in...
Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Dainippon’s Cynata Quest Falls Through As Sides Remain Apart
Japanese firm backs off potential acquisition of Australian cell therapy venture after the two sides fail to agree on deal terms.
Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.